The National Institute for Health and Care Excellence (NICE) has recommended brentuximab vedotin combined with doxorubicin, ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

The UK’s health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended brentuximab ...

Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy ...

HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or ...

The most common (≥25%) adverse reactions, including laboratory abnormalities, in patients receiving tisotumab vedotin were peripheral neuropathy (39%), nausea (37%), epistaxis (33% ...

A novel cell therapy approach using natural killer cells pre-complexed with a bispecific antibody, was safe and generated ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

It is estimated that about 800 people with Hodgkin lymphoma could benefit from the decision by the National Institute for ...

The most common (≥25%) adverse reactions, including laboratory abnormalities, in patients receiving tisotumab vedotin were peripheral neuropathy (39%), nausea (37%), epistaxis (33%), conjunctivitis ...